Envista (NVST) Stock Price, News & Analysis

Company Overview

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments. Its integrated approach enables dental professionals to access consumables, equipment and digital workflow tools through a unified platform, helping to streamline procedures and enhance patient care. The company supports research and development initiatives aimed at advancing digital dentistry and improving clinical outcomes.

Envista was established in July 2019 following its spin-off from Danaher Corporation, bringing together decades of dental industry expertise under a dedicated corporate structure. Since its inception, Envista has expanded its geographic reach and invested in strategic partnerships to drive innovation and market penetration. The company’s leadership team, led by a chief executive officer and experienced executives in operations, marketing and research, focuses on long-term growth through product development, acquisitions and operational excellence.

Key Stats

• Today's Range: $25.43 to $26.34
• 50-Day Range: $24.31 to $29.59
• 52-Week Range: $16.32 to $30.42
• Volume: 2.09 million shs
• Average Volume: 2.72 million shs
• Market Capitalization: $4.27 billion
• P/E Ratio: 93.53
• Dividend Yield: N/A
• Price Target: $28.25
• Consensus Rating: Hold

Envista Stock Analysis - MarketRank™

Envista scored higher than 32% of companies evaluated by MarketBeat, and ranked 692nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Hold

Consensus Rating

Envista has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 6 buy ratings, 9 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Envista is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Envista has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.71%

Earnings Growth

Earnings for Envista are expected to grow by 10.71% in the coming year, from $1.40 to $1.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Envista is 93.53, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Envista is 93.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.04.

Price to Earnings Growth Ratio

Envista has a PEG Ratio of 1.80. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Envista has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.83% of the float of Envista has been sold short.

Short Interest Ratio / Days to Cover

Envista has a short interest ratio ("days to cover") of 5.47.

Change versus previous month

Short interest in Envista has recently increased by 13.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Envista does not currently pay a dividend.

Dividend Growth

Envista does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Envista has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Envista this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Envista insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $290,250.00 in company stock.

Percentage Held by Insiders

0.99% of the stock of Envista is held by insiders.

Percentage Held by Institutions

Envista has minimal institutional ownership at this time.

NVST Stock Analysis - Frequently Asked Questions

How have NVST shares performed this year?

Envista's stock was trading at $21.72 at the beginning of the year. Since then, NVST stock has increased by 20.6% and is now trading at $26.1870.

How were Envista's earnings last quarter?

Envista Holdings Corporation (NYSE:NVST) issued its earnings results on Thursday, February, 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.32 by $0.06. The firm's quarterly revenue was up 15.0% compared to the same quarter last year.
Read the conference call transcript.

When did Envista IPO?

Envista (NVST) raised $602 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 26,768,000 shares at $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley served as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

Who are Envista's major shareholders?

Top institutional investors of Envista include Pzena Investment Management LLC (0.98%), Bank of New York Mellon Corp (0.80%), Capricorn Fund Managers Ltd (0.46%) and Principal Financial Group Inc. (0.30%). Insiders that own company stock include Amir Aghdaei, Eric Conley, Mark E Nance, Mischa Reis, Eric D Hammes and Stephen Keller.
View institutional ownership trends.

How do I buy shares of Envista?

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Envista own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Envista investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 2/05/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NVST
• CIK: 1757073
• Web: www.envistaco.com
• Phone: 714-817-7000
• Fax: 714-817-5450
• Employees: 12,000
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Envista: $28.25
• High Price Target: $35.00
• Low Price Target: $21.00
• Potential Upside/Downside: +7.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.28
• Trailing P/E Ratio: 93.53
• Forward P/E Ratio: 18.71
• P/E Growth: 1.8
• Net Income: $47 million
• Net Margins: 1.73%
• Pretax Margin: 6.52%
• Return on Equity: 6.54%
• Return on Assets: 3.60%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 2.38
• Quick Ratio: 2.04

Sales & Book Value

• Annual Sales: $2.72 billion
• Price / Sales: 1.57
• Cash Flow: $2.16 per share
• Price / Cash Flow: 12.13
• Book Value: $18.89 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 162,981,000
• Free Float: 161,367,000
• Market Cap: $4.27 billion
• Optionable: Optionable
• Beta: 0.92